For the quarter ending 2026-03-31, VYCO had $86,652 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 20,108 | -62,686 | 4,936 | -14,676 |
| Stock based compensation | - | 0 | 12,209 | 36,629 |
| Depreciation of fixed assets | 15,668 | 16,144 | 15,868 | 31,131 |
| Allowance for doubtful accounts - accounts receivable | 8,340 | 0 | 2,690 | 0 |
| Accounts receivable | -16,510 | -107,161 | 126,074 | -42,591 |
| Inventory | -10,970 | 7,056 | -6,568 | 8,304 |
| Prepaid expenses | 4,232 | -6,244 | 19,993 | 10,614 |
| Accrued interest - related party | 12,571 | 12,571 | -2,429 | 25,142 |
| Accrued interest | 11,836 | 12,099 | 12,098 | 23,803 |
| Accounts payable | 5,712 | -8,065 | -17,221 | -37,527 |
| Accrued liabilities | 822 | -37,488 | 38,868 | -68,726 |
| Changes in discontinued operations, net | 1,117 | 308 | 53 | 275 |
| Cash provided by (used in) operating activities | 99,422 | 39,232 | -72,427 | 19,724 |
| Purchase of fixed assets | - | 1,605 | 1 | 3,618 |
| Sale or disposal of fixed assets | 2,140 | -1 | 1 | 841 |
| Cash provided by investing activities | 2,140 | -1,606 | 0 | -2,777 |
| Proceeds - notes payable other | - | 0 | 59,024 | 0 |
| Repayments - notes payable other | 14,910 | 14,874 | 22,067 | 22,895 |
| Cash used in financing activities | -14,910 | -14,874 | 36,957 | -22,895 |
| Effect of exchange rate changes on cash | - | - | - | 0 |
| Net increase (decrease) in cash | 86,652 | 22,752 | -35,470 | -5,948 |
| Cash at beginning of period | 86,982 | 64,230 | 105,648 | - |
| Cash at end of period | 173,634 | 86,982 | 64,230 | - |
VYCOR MEDICAL INC (VYCO)
VYCOR MEDICAL INC (VYCO)